By Gilang Cahya 
A groundbreaking study by researchers at the Ludwig Cancer Research has unveiled a complex and surprising relationship between dietary components, the intricate ecosystem of intestinal microbes, and the effectiveness of certain cancer therapies. This discovery holds significant implications for how cancer treatments are prescribed and managed, potentially paving the way for more personalized and effective therapeutic strategies. The research, spearheaded by Asael Roichman of Ludwig Princeton and Branch Director Joshua Rabinowitz, offers a compelling explanation for why PI3 kinase (PI3K) inhibitors, a class of drugs designed to halt cancer cell proliferation by targeting an overactive signaling pathway, have not consistently yielded durable responses in patients with solid tumors.
The variability in patient response to cancer therapies has long been a puzzle for oncologists. While genetic predispositions and tumor characteristics are well-established factors, the influence of lifestyle elements like diet has been an area of growing interest. “Many cancer drugs don’t work equally well for all patients, and one emerging possibility is that diet plays a role in this variability,” stated Dr. Rabinowitz, a leading figure in cancer research. “We found in this study that diet can indeed alter cancer treatment outcomes in preclinical models and can do so in an unexpected way, unrelated to its immediate nutritional effects. It turns out that certain small molecules in plant-based foods are transformed in mice by commensal gut bacteria into compounds that activate the liver to clear PI3K inhibitors more quickly, lowering the efficacy of the drug.”
This unexpected mechanism, revealed through meticulous experimentation, suggests that dietary choices, mediated by gut bacteria, can directly impact the systemic availability and thus the therapeutic potency of crucial cancer medications. The liver plays a central role in metabolizing and clearing drugs from the body, and the study identifies a specific pathway influenced by diet and microbes that accelerates this process for PI3K inhibitors.
Unraveling an Unexpected Link: From Ketogenic Diets to Phytochemicals
The study’s origins are rooted in an intriguing observation that diverged from prevailing scientific assumptions. Previous research from the Rabinowitz lab and others had demonstrated that ketogenic diets, characterized by high fat and very low carbohydrate content, could significantly enhance the effectiveness of cancer drugs in preclinical mouse models. This enhancement was widely attributed to the ketogenic diet’s ability to lower insulin and blood sugar levels, factors known to influence cancer cell metabolism.
However, the current study encountered a perplexing anomaly: mice fed certain high-carbohydrate diets, which would typically be expected to increase blood sugar and insulin, paradoxically showed robust responses to PI3K inhibitors. This unexpected outcome prompted the researchers to delve deeper, questioning the established hypotheses. Their investigation, detailed in the latest issue of the scientific journal Cell, revealed that the key determinant was not the macronutrient composition of the diet – carbohydrates, fats, blood sugar, or insulin – but rather the molecular complexity of the food itself. Specifically, the distinction lay between "whole foods" and highly processed alternatives.
The ketogenic diet formulation used in prior preclinical studies, while effective, was a highly processed product. Crucially, it lacked the diverse array of plant-derived chemicals, known as phytochemicals, that are abundant in standard animal chow, particularly those found in legumes and soy. It was this absence of specific phytochemicals that ultimately provided the clue.
The Gut Microbiome’s Microbial Alchemy: Phytochemicals to Drug Metabolism
The research team discovered that specific phytochemicals, notably soyasaponins derived from soybeans, are processed by gut microbes. These commensal bacteria act as tiny biochemical factories, transforming these plant-derived molecules into novel compounds. These transformed compounds, in turn, were found to induce the expression of a crucial liver enzyme: cytochrome P450.
Cytochrome P450 enzymes are a superfamily of monooxygenases primarily responsible for metabolizing a vast range of endogenous and exogenous compounds, including drugs. The study demonstrated that an elevated production of these hepatic enzymes, triggered by the breakdown products of soyasaponins, led to a significantly accelerated clearance of PI3K inhibitors from the bloodstream in the mice. This rapid drug clearance directly translated to a diminished anti-cancer efficacy of the therapeutic regimen.
To further validate this hypothesis, the researchers conducted a series of targeted experiments. They observed that a high-carbohydrate diet with a low phytochemical content produced similar results to the processed ketogenic diet, leading to enhanced PI3K inhibitor activity. Moreover, the administration of antibiotics, which are known to disrupt the delicate balance of the gut microbiome, also resulted in an amplification of PI3K inhibitor efficacy in the mice. This provided strong evidence that the gut bacteria were indeed the critical intermediaries in this dietary-drug interaction.
“These findings suggest that some plant-based diets, through their interactions with gut microbes, may lower cancer drug exposure by ramping up the body’s drug clearance systems,” explained Roichman, the lead author of the study. “While the specific molecules that exert such an influence may differ in humans, our work highlights diet and the microbiome as key factors that can shape how cancer drugs behave in the body.”
Broader Implications for Cancer Therapy and Beyond
The implications of this research extend far beyond the specific class of PI3K inhibitors. The liver enzymes involved in clearing these drugs, particularly cytochrome P450 isoforms, are responsible for metabolizing a wide array of medications, including many other chemotherapeutics and drugs used to treat a multitude of diseases.
“While we focused in this study on PI3K inhibitors, the liver enzymes involved in clearing these drugs break down many others as well,” Roichman emphasized. “This suggests our findings could be of relevance to multiple classes of drugs used to treat cancer and other diseases.”
This groundbreaking work opens up new avenues for optimizing cancer treatment strategies. It underscores the need to consider a patient’s dietary habits, the composition of their gut microbiome, and even recent antibiotic use – all factors that can profoundly influence the complex ecosystem of commensal bacteria within the digestive tract.
Future Directions and Personalized Medicine
The findings presented in Cell pave the way for innovative approaches in cancer care. Future research could focus on developing diagnostic tools to assess a patient’s microbiome profile and identify individuals who might be more susceptible to reduced drug efficacy due to their dietary habits and microbial makeup. This could lead to personalized dietary recommendations or even the prescription of specific probiotics or prebiotics to modulate the gut microbiome in favor of enhanced drug activity.
Furthermore, the study suggests the potential for pharmaceutical interventions designed to fine-tune the metabolic pathways involved in drug clearance. This could involve developing drugs that temporarily inhibit specific liver enzymes or compounds that modulate the activity of gut bacteria.
The integration of dietary and microbial analyses into cancer treatment protocols could usher in an era of truly personalized medicine. By understanding how a patient’s unique biological landscape interacts with their prescribed therapy, clinicians can move beyond a one-size-fits-all approach to optimize treatment outcomes and minimize adverse effects.
The research team, led by Dr. Rabinowitz, who also serves as Professor in the Department of Chemistry & Lewis-Sigler Institute for Integrative Genomics and is a Member of the Rutgers Cancer Institute, acknowledges the need for further investigation to confirm these findings in human populations. However, the preclinical data provides a robust foundation for optimism.
This study was made possible through the generous support of the Ludwig Institute for Cancer Research, Stand Up 2 Cancer, the U.S. National Institutes of Health, and the New Jersey Commission on Cancer Research, highlighting the collaborative and multi-faceted nature of advancing cancer research. The discovery serves as a powerful reminder that the intricate interplay between our diet, our internal microbial partners, and the medications we take can have profound and often unexpected consequences for our health.
